These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

799 related items for PubMed ID: 10652035

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. National perspective on iron therapy as a clinical performance measure for maintenance hemodialysis patients.
    Owen WF, Szczech L, Johnson C, Frankenfield D.
    Am J Kidney Dis; 1999 Oct; 34(4 Suppl 2):S5-S11. PubMed ID: 10516369
    [Abstract] [Full Text] [Related]

  • 3. Erythropoietin and iron use in peritoneal dialysis patients. Report from the 1997 HCFA end-stage renal disease core indicators project.
    Bailie GR, Frankenfield DL, Prowant BF, McClellan W, Rocco MV.
    Am J Kidney Dis; 1999 Jun; 33(6):1187-9. PubMed ID: 10352214
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: Results from the 1998 End-Stage Renal Disease Core Indicators Project.
    McClellan WM, Frankenfield DL, Wish JB, Rocco MV, Johnson CA, Owen WF, End-Stage Renal Disease Core Indicators Work Group.
    Am J Kidney Dis; 2001 May; 37(5):E36. PubMed ID: 11325701
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness impact of iron dextran on hemodialysis patients' use of epoetin alfa and blood.
    Driver PS.
    Am J Health Syst Pharm; 1998 Dec 15; 55(24 Suppl 4):S12-6. PubMed ID: 9872688
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
    Pussell BA, Walker R, Australian Renal Anaemia Group.
    Nephrology (Carlton); 2007 Apr 15; 12(2):126-9. PubMed ID: 17371333
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Relative contributions of body iron status and uremia severity to anemia in patients with advanced chronic renal failure.
    Ifudu O, Dawood M, Friedman EA.
    Nephron; 1997 Apr 15; 77(3):315-8. PubMed ID: 9375826
    [Abstract] [Full Text] [Related]

  • 14. Anemia management trends in hospital-based dialysis centers (HBDCs), 2010 to 2013.
    Coritsidis GN, Maglinte GA, Acharya A, Saxena A, Chang CL, Hill J, Gitlin M, Lafayette RA.
    Clin Ther; 2014 Mar 01; 36(3):408-18. PubMed ID: 24582713
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A prospective open-label study evaluating the efficacy and adverse reactions of the use of Niferex-150 in ESRD patients receiving EPOGEN.
    Johnson CA, Rosowski E, Zimmerman SW.
    Adv Perit Dial; 1992 Mar 01; 8():444-7. PubMed ID: 1361844
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Anemia management and treatment response in patients on hemodialysis: the MAR study.
    Portolés J, López-Gómez JM, Aljama P.
    J Nephrol; 2006 Mar 01; 19(3):352-60. PubMed ID: 16874697
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.